Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Again Increases Tongjitang Stake

publication date: Feb 6, 2009

Shanghai Fosun Pharmaceutical (Group) Co. has upped its stake in Tongjitang Chinese Medicines (同济堂药业) to 13.2%. It was the eighth purchase of Tongjitang that Fosun has made, and it brings the total number of Tongjitang shares it owns to 17.8 million. The 17.8 million shares equate to 4.5 million ADSs (each ADS is equivalent to 4 ordinary shares; the ADSs trade on the NYSE). More details...

Stock Symbols: (SHSE: 600196) (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital